Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Lymphoma

Drugs for Lymphoma
Find financial assistance programs available for lymphoma drugs. Read More ›

Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma

You Only Live T-W-I-C-E: A Cancer Warrior's Motto
Receiving a diagnosis of stage IIIB diffuse large B-cell non-Hodgkin lymphoma at age 26 at the start of COVID-19 meant that Steffi Ilagan had to sideline a lot of her plans. Her story illuminates the meaning of “T-W-I-C-E” when facing cancer. Read More ›

Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma

Yescarta First CAR T-Cell Therapy FDA Approved for Patients with Large B-Cell Lymphoma

Kymriah, a CAR T-Cell Immunotherapy, FDA Approved for Patients with Follicular Lymphoma

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
In September 2021, the FDA approved Brukinsa oral capsules for adults with relapsed or refractory marginal-zone lymphoma. And in August, the FDA approved Brukinsa for adults with Waldenström’s macroglobulinemia, a rare, slow-growing type of non-Hodgkin lymphoma. Read More ›

Adding Venclexta to Revlimid and Rituxan Leads to Undetectable Cancer in Mantle-Cell Lymphoma

FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection. Read More ›

Zynlonta First FDA-Approved CD19-Targeted Therapy for Large B-Cell Lymphoma
In April 2021, the FDA approved Zynlonta (loncastuximab tesirine), the first CD19-directed antibody–drug conjugate, for the treatment of patients with relapsed or refractory large B-cell lymphoma. Read More ›

Page 1 of 6